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Abstract 
 
Background: Psoriasis worldwide prevalence is estimated between 1% and 3%. In Greece, prevalence is around 2% 
and affects approximately 200.000 patients. The most common form of the disease is chronic plaque psoriasis that 
affects about 80% of psoriasis patients of which more than 10% present a moderate or severe form of the disease. Data 
and information concerning the quality of life of the patients with a moderate and severe condition, and the economic 
impact of the disease is limited worldwide and particularly in European countries. The primary objective of this study 
was to evaluate the quality of life of patients with moderate and severe psoriasis, an intangible cost of the illness, as 
well as to evaluate the economic impact of the illness in Greece from patient and third-party payer (insurance funds) 
perspectives.  
Methods/Design: Two different questionnaires, SF36 and DLQI were used to evaluate patients’ quality of life (QoL). 
Evaluation  of  the  economic  impact  of  the  disease  was  done  by  identifying  the  direct  heath  care  cost,  through  a 
microeconomic evaluation of all the health care costs, and the loss of productivity, using the human capital approach. 
Our study included consecutive patients from the Venereal and Skin Diseases Hospital “Andreas Syggros” in Athens, 
during the period January-December 2005. The inclusion criteria were: age > 18 yrs, PASI (Psoriasis Area Severity 
Index)  >12 and BSA (Body Surface Area)  >10%. Patients enrolled in the study were re-assessed after a 3-month 
period, which was set as the observation period.  
Results:  The sample for the quality of life assessment study included 177 patients. Ninety-seven patients were re-
assessed after the three-month period and their data were used to evaluate the economic impact of the illness.  The 
majority of patients in the study were men with a mean age of around 50. According to the results, both moderate and 
severe psoriasis affect negatively the patients’ quality of life in every aspect examined. In particular, it mostly affects 
their mental and emotional situation. During their first visit, the patients mean score of PASI was 20.17 and BSA was 
29.81%.  During  the  patients’  2
nd  visit,  3-months  later,  the  mean  PASI  and  BSA  scores  were  8.44  and  14.89% 
respectively. Specifically, 67 out of the 97 patients (69.1%) achieved a PASI 50, whereas 37 of them (38.1%) achieved 
a PASI 75. The economic consequences of the illness are extremely high, since the average total cost per patient was 
estimated to be €12,455.91 per year. In part this is due to the chronic state of the disease, but is mainly due of the 
induction of biological medicines in the disease management 
Conclusion: Moderate and severe plaque psoriasis has a profound impact on the affected Greek patient’s QoL and is 
associated with extremely high costs. Although biological medicines can contribute to improvements of patient’s QoL 
strictest compliance with disease management guidelines as well as introduction of generic biological medicines will 
significantly mitigate the increasing cost of this chronic disease. 
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Background 
 
Health economics is of growing importance in 
all  health-care  systems.  Precise  cost  data  are 
needed for decisions in health care and health 
policy  making.  Therefore,  economic 
evaluations  are  necessary  in  order  to  make 
appropriate  use  of  different  treatment  options 
(Williams  et  al  2008).  Cost-of-illness  studies 
are  a  well-recognized  tool  to  evaluate  the 
financial burden of diseases in a country and to 
identify  subgroups  for  which  the  costs  are 
particularly high (Ament A and Evers S 1993). 
Psoriasis  is  an  autoimmune  chronic 
inflammatory  skin  disorder  that  worldwide 
affects approximately 1–3% of the population 
(Nevitt & Hutchinson 1996, Plunkett et al 1998, 
Naldi
 2004). In Greece, prevalence is estimated 
at around 2% and affects about 200.000 people.  
The  most  common  form  of  the  disease  is 
chronic plaque psoriasis that affects about 80-
90%  of  psoriasis  patients  of  which  20-30% 
present  a  moderate  or  severe  form  of  the 
disease  (Sterry  et  al  2004).  The  chronic  and 
aesthetically  unpleasant  nature  of  the  disease 
affects  negatively  the  patients’  quality  of  life 
(Krueger et al  2001).  
Psoriasis  severity  is  defined  by  the  extent  of 
body surface involved, the lesion characteristics 
and the impact of the disease on quality of life 
(QoL) (Finlay et al 2005). Patients with a body-
surface  involvement  higher  than  10%,  or  a 
Psoriasis Area Severity Index (PASI)>10, or a 
Dermatology  Life  Quality  Index  (DLQI)  >10 
are  considered  appropriate  candidates  for 
systemic therapy (Kirby et al 2000, Shikiar et al 
2003, Menter A. et al 2008). More than 10% of 
the patients also have psoriatic arthritis (Veale 
& FitzGerald, 2002, Parisier et al 2007).  
The  disease  is  usually  persistent  and 
progressive and patients usually need lifelong 
care, which also means a lifetime of expenses 
(Galadari  et  al  2001).  From  an  economic 
perspective, many influencing factors must be 
taken into account, such as the costs related to 
prescription drugs, over-the-counter (OTC) and 
self-care products, hospitalizations, productivity 
loss due to absence from work for sick leave, 
and  time  spent  by  patients  in  medical 
consultations,  treatments,  or  diagnostic 
procedures (Braathen et al 2001, Dehkharghani 
et al 2003). Limited information about quality 
of life and the economic impact of psoriasis in 
European countries is available, especially after 
the induction of the biological medicines in the 
treatment  of  the  illness  (Naldi  L  2005). 
Therefore, we conducted a study to evaluate the 
patient’s  quality  of  life,  the  direct  healthcare 
costs  and  the  loss  of  productivity  related  to 
moderate and severe plaque psoriasis in Greece.  
 
Patients and methods 
 
Design 
  
We  collected  QoL  data  using  two 
questionnaires.  The  SF36  (short  form,  36 
questions) general health status survey and the 
Dermatology  Life  Quality  Index  (DLQI) 
questionnaire,  a  10-item  dermatology  specific 
instrument.  We  carried  out  a  3-month 
observational, prospective cost-of-illness study 
of moderate and severe plaque psoriasis. Direct 
healthcare costs and loss of productivity were 
considered  from  the  patient  and  third-party 
payer  (insurance  funds)  point  of  view.  The 
study  design  included  also  two  medical 
examinations, at baseline and after 3 months. 
From  January  2005  through  December  2005, 
patients  with  moderate  and  severe  psoriasis 
attending  the  Venereal  and  Skin  disease 
Hospital  “Andreas  Syggros”  in  Athens  were 
invited to participate in the study. Consecutive 
patient enrolments occurred over 1 year in order 
to minimize seasonal fluctuations.  
 
Inclusion criteria 
 
Patients aged 18 years and above with moderate 
to  severe  plaque  psoriasis  defined  as  PASI 
score  higher  than  12  and  a  BSA  higher  than 
10% were included in the study. PASI and BSA 
score  are  the  most  accepted  and  widely  used 
measures  to  assess  disease  severity  and 
improvement  in  clinical  trials  and  practice 
(Richard G
 et al 2004). The study was approved 
by  the  local  ethical  committees  and  the 
Declaration  of  Helsinki  protocols  were 
followed.  Written  informed  consent  was 
obtained from all participants. 
 
Data collection 
 
Patients were invited to participate in the study 
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At the dermatological examination (Visit 1), the 
evaluating  physician  completed  the 
“dermatologist  questionnaire”,  containing  data 
on medical history, physical examination, and 
any  concomitant  drug  both  topic,  systemic 
(such  as  methotrexate,  cyclosporine  etc)  and 
biological.  During  the  first  visit,  patients 
completed  the  two  self-administered 
questionnaires, DLQI and SF-36. Patients also 
were  given  another  self-administered 
questionnaire named “patient questionnaire”, to 
be  completed  on  the  first  and  second 
examinations.  The  “patient  questionnaire” 
registered  data  on  socio-demographic 
characteristics  and  loss  of  productivity.  
Patients  were  asked  to  keep  all  drug  packs 
(including cream tubes) that would be used in 
the  next  quarter,  in  order  to  verify  real  drug 
consumption  (compliance).  Patients  were 
evaluated  again  after  3  months  (±15  days) 
during  their  second  visit.  The  following  data 
were  collected:  results  of  physical  and 
laboratory  examinations  (including  diagnostic 
procedures),  the  number  and  time  of 
hospitalizations,  concomitant  drugs,  non-
conventional  treatments,  concurrent  visits  by 
dermatologists  and  other  medical  specialists, 
and working days lost in the previous quarter. 
 
Quality of life 
In order to assess the patients’ quality of life, 
they  were  asked  to  fill  in  the  SF-36  and  the 
DLQI  questionnaires.  The  SF-36  is  a  multi-
purpose,  short-form  health  survey  with  36 
questions (Ware JE and Donald Shebourne C 
1992,  Ware  et  al  1993,  Ware  et  al  2000).  It 
yields  an  8-scale  profile  of  functional  health 
and  well-being  scores,  as  well  as 
psychometrically  based  physical  and  mental 
health  summary  measures,  and  a  preference-
based  health  utility  index.  It  is  a  generic 
measure,  as  opposed  to  one  that  targets  a 
specific age, disease, or treatment group. The 
DLQI is a dermatology-specific measure which 
consists  of  10  questions  related  to  patient’s 
symptoms and feelings, daily activities, leisure, 
work  or  school,  personal  relationships  and 
treatment over the previous one week. The total 
DLQI ranges from 0 (no impairment of QoL) to 
30 (maximum impairment of QoL) (Finlay AY 
and Kahn GK 
 1994, Lewis V and Finlay AY 
2004). 
 
Costing 
 
The direct health sector costs and the patients’ 
loss of productivity of the present study were 
assessed as follows: 
1.  Direct costs 
Medical costs studied were: a) hospitalization, 
b)  day-hospital  admissions,  c)  specialist 
medical  examinations,  d)  laboratory  tests  and 
diagnostic procedures, e) phototherapy, f) drug 
therapies. These costs are based upon the fixed 
prices set by the Ministry of Health (2005) and 
paid  by  health  insurance  funds.  Heath  care 
services  provided  by  the  private  sector  and 
other private costs were evaluated based on the 
actual expenses incurred in by the patients. All 
pharmacological  therapies  (topical,  systemic 
and  biological)  were  considered  in  the 
questionnaire. To assess the costs of prescribed 
pharmacological  therapies,  units  of  consumed 
resources were multiplied by the prices reported 
in  the  official  Greek  price  list,  taking  into 
consideration  the  dosage  and  duration  of  the 
treatment.  Non  conventional  treatments  were 
also assessed. All costs are expressed in Euros. 
2. Loss of productivity 
The  human  capital  approach  was  used  to 
estimate  the  productivity  loss  due  to  plaque 
psoriasis (Luce et al 1996). Travel costs were 
not collected. Loss of productivity included the 
value  of  lost  production  due  to  leaving  work 
earlier  than  usual  in  the  day  and  sick  leave. 
Patients’ time off work was measured in terms 
of salary evaluation, with the assumption that 
income  reflects  productivity.  The  monetary 
value  of  1  lost  working  day  for  patients  was 
calculated  as  €27,  equal  to  the  wage  of  an 
unskilled worker in 2005.  
 
Statistical Analysis 
 
Statistical analysis were performed using SPSS 
(version 13.0) Firstly, exploratory data analyses 
were  performed  in  order  to  provide  all  the 
frequencies  on  all  variables  of  the 
questionnaire.  These  descriptive  analyses 
included  distribution  patterns  (ranges,  means, 
medians,  skewness),  missing  values,  and 
outliers on quantitative variables.  International Journal of Caring Sciences      2012   May-August   Vol 5  Issue 2 
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The statistical methods included t-test and chi-
square  test  for  categorical  variables  such  as 
employment status, marital status, gender etc. 
 
Results 
 
1. Quality of life study 
Population 
Table 1 illustrates the main socio-demographic 
and disease characteristics regarding the quality 
of life study. The mean age of the 177 patients 
examined  (119  males  (67%)  and  58  females 
(33%))  was  49.85  years. The  majority  (n=99, 
55.9%)  were  employed,  while  44.1%  (n=78) 
were unemployed or retired. Also, the majority 
(n=140, 79%) were married, while 21% (n=37) 
were single, divorced or widow. The mean age 
during the first diagnosis was 33.16 years. The 
mean  PASI  score  was  20.25  and  mean  BSA 
score was 29.8% 
 
SF36 and DLQI scores 
Tables  2,  and  3  show  the  SF36,  and  DLQI 
questionnaires scores. The worst scores on the 
SF36  questionnaire  were  recorded  on  the 
General  Health  and  Mental  Health  scales. 
Figure  1  compares  the  results  of  the  SF-36 
questionnaire in the study population with the 
mean values of the general population (Pappa 
E. et al, 2005). All the scores were below the 
mean,  thus  confirming  the  high  impact  of 
plaque psoriasis on the QoL of patients. On the 
DLQI questionnaire, the worst score was with 
respect to the Symptoms and Feelings subscale, 
proving the psychological impact of the disease. 
 
2. Cost-of-illness study 
Population 
Table 1 also shows the main socio-demographic 
and disease characteristics regarding the cost-
of-illness  study.  The  mean  age  of  the  97 
patients  examined,  72  males  (74%)  and  25 
females (26%), was 49.73 years. The majority 
(n=56,  60.8%)  were  employed,  while  39.2% 
(n=38) were unemployed or retired. Also, the 
majority  (n=84,  79%)  were  married,  while 
13.4% (n=13) were single, divorced or widow. 
The  mean  age  at  first  diagnosis  was  33.28 
years.  The  mean  PASI  score  was  20.17  and 
mean BSA score was 29.81% 
Treatment pattern 
Treatment  patterns  at  baseline  (Visit  1)  are 
shown  in  Table  4.  During  the  3  months,  the 
majority of patients received topical treatment 
(80%)  and  systemic  therapy,  non-biological 
(47%)  or  biological  (52%).    The  number  of 
hospitalizations  and  medical  examinations  is 
significantly high, involving 39 (40.2%) and 83 
(85.6%) patients respectively. 
 
Resource utilization and absence from work 
The  consumption  of  medical  services  and 
medications during the 3 months is shown in 
Table 5. The mean total cost per patient (direct 
health care cost plus loss of productivity) was 
€12,455.91 per year. Direct costs accounted for 
95.7% of the total estimated disease costs for 
moderate and severe plaque psoriasis. The most 
significant  direct  costs  pertained  to  biological 
medicines (77.97%) followed by hospitalization 
(9.8%), while costs due to topical or systemic 
non-biological  therapy  only  accounted  for 
0.82% and 3.49% respectively. 
The  expenses  incurred  for  psoriasis  treatment 
were  significantly  higher  in  those  patients 
treated  with  biological  medicines  than  in 
patients that were treated without (Table 5).  
The annual costs per patient that were treated 
without  biological  medicines  amounted  to        
€ 3,856.85, while the costs per patient that was 
treated  with  biological  medicines  were  € 
25,244.26, which is >6.5 times more. The cost 
differences  between  these  two  groups  of 
patients  were  predominantly  due  to  the  huge 
costs  of  biological  medicines.  The  most 
significant  cost  to  those  patients  that  weren’t 
treated  with  biological  medicines  was 
hospitalization  which  represented  48.61%  of 
the total expenses.  This was followed by the 
loss of productivity that represented 20.66% of 
the total expenses.  
However,  the  prescriptions  of  biological 
medicines  are  associated  with  a  statistical 
significant  decrease  in  loss  of  productivity. 
Moreover,  a  non  statistical  significance 
reduction  in  ambulatory  visits,  diagnostic 
procedures and hospitalization, was noted. . 
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Table 1: Demographic and disease characteristics in moderate and severe psoriasis 
 
 
 
 
Table 2:  SF36, Quality of life measurement at visit 1 
 
  n=177  SD 
Scales  Score   
Physical Functioning, PF  78,6  23,6 
Role Physical, RP  77,3  36,1 
Bodily Pain, BP  71  29,1 
General Health, GH  52,4  22,3 
Vitality, VT  65,1  19,7 
Social Functioning, SF  80,7  25,7 
Role Emotional, RE  77,4  39,8 
Mental Health, MH  57  19,2 
Physical Component Summary, PCS  47,9  - 
Mental Component Summary, ΜCS  45,9  - 
 
Table 3: DLQI means score and categories scores 
Mean score  SD 
6.07  6.18 
Category  Score 
Symptoms and feelings  35,8% 
Daily activities  21,3% 
Leisure  12,2% 
Work and school  14,9% 
Personal relationships  14,1% 
Treatment  20,72% 
 
  Quality of life study  Cost of illness study 
  N and/or %  SD  N and/or %  SD 
N  177  -  97  - 
Mean age in years  49.85  14.86  49.73  13.96 
Sex (male)  119 (67%)  -  72 (74%)  - 
Sex (female)  58 (33%)  -  25 (26%)  - 
Mean age at first diagnosis 
(years) 
33.16  16.23  33.28  15.63 
Mean PASI  at first visit  20.25  7.7  20.17  6,48 
Mean BSA  at first visit  29.8%  13.07  29.81%  11.62 
Mean PASI at second visit  -  -  8.44  5.98 
Mean BSA at second visit  -  -  14.89  8.78 
Employed  99 (55.9%)  -  59 (60.8%)  - 
Unemployed, Retired  78 (44.1%)  -  38 (39.2%)  - 
Married  140 (79%)  -  84 (86.6%)  - 
Single, divorced, widow  37 (21%)  -  13 (13.4%)  - International Journal of Caring Sciences      2012   May-August   Vol 5  Issue 2 
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Table 4: Treatment pattern during the 3 months 
  N  % 
Topic  78  80 (%) 
Systemic (non-biological medicines)  46  47 (%) 
Phototherapy  17  18 (%) 
Non-conventional  treatments  (Homeopathy,  Bach’s  flowers, 
Balneotherapy etc) 
39  40 (%) 
Biological medicines  39  40.2 (%) 
a Efalizumab   17  18 (%) 
b Etenercept  17  18 (%) 
c Infliximab  5  5 (%) 
Hospitalization  39  40.2 (%) 
Medical examinations  83  85.6 (%) 
 
Table 5: Direct health care and loss of productivity costs per year 
  N=97  Non-biological 
medicines N=58 
Biological medicines 
N=39 
  Total €  Per patient 
€ 
%  Per 
patient 
%  Per patient  % 
Direct health care cost  1.156.167,32  11.919,25  95,7  3059.88  79.34  25094.72  99.41 
Hospitalization  118.000,00  1.216,49  9,8  1875.00  48.61  237.18  0.94 
Ambulatory visits  4.540,00  46,80  0,4  43.66  1.13  51.49  0.20 
Pharmacological 
treatment  994.110,24  10.248,56  82,3  736.15  19.09  24395.22  96.64 
Topic  9.857,20  101,62  0,82  124.90  3.24  67.00  0.27 
Systemic  
(non-biological)  42.160,12  434,64  3,49  611.25  15.85  171.99  0.68 
Biological medicines  942.092,88  9.712,30  77,97  0  0  24156.23  95.69 
Phototherapy  1.284,84  13,25  0,1  22.15  0.57  0  0 
Laboratory 
examinations   26.032,24  268,37  2,2  251.89  6.53  117.95  0.47 
Non-conventional 
treatments  12.200,00  125,77  1  131.03  3.40  292.89  1.16 
Loss of productivity  52.056,00  536,66  4,3  796.97  20.66  149.54  0.59 
Total cost  1.208.223,32  12.455,91  100  3856.85  100  25244.26  100 
0
20
40
60
80
100
Moderate to severe psoriasis
patients
78,6 77,3 71 52,4 65,1 80,7 77,4 57 47,9 45,9
General population 80,8 79,7 73 67,5 66,5 82,1 81,5 68,2 49,1 49,2
PF RP BP GH VT SF RE MH PCS MCS
 
Figure 1: SF36: Quality of life measurements at visit I compared to the mean for the Greek 
population
10 
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Effectiveness of the treatment 
The patients that enrolled in the study during the 1st 
visit  were  found  to  have  a  mean  score  of  PASI: 
20.17 and BSA: 29.81%. Despite the treatment used, 
being  the  conventional  methods  (topic  medicines, 
phototherapy  and  systemic  but  non  biological 
medicines, such as cyclosporine and methotrexate) 
or  with  the  introduction  of  biological  medicines, 
clinical results were successful. During the patients’ 
2
nd visit, 3-months later, the mean PASI and BSA 
scores  were  8.44  and  14.89%  respectively. 
Specifically,  67  out  of  the  97  patients  (69.1%) 
achieved  a  PASI  50  (which  means  50% 
improvement  of  the  PASI  index),  whereas  37  of 
them  (38.1%)  achieved  a  PASI  75  (which  means 
75% improvement of PASI index). 
 
Discussion 
Plaque  psoriasis  is  a  very  common  cutaneous 
disease which may have a profound impact on the 
affected  person’s  QoL  and  a  substantial  economic 
impact for the patients and the health care system. In 
spite of this, only a few studies have been performed 
with little attention to presenting an overall picture 
of  the  costs  of  care  for  patients  with  psoriasis, 
especially after the induction of biological medicines 
in the treatment of the illness. This also applies to 
Greece,  where  little  is  known  about  the 
epidemiology,  the  patients’ quality  of  life  and  the 
economics of psoriasis.  
According to our study on the quality of life and the 
cost  of  illness  of  moderate  and  severe  plaque 
psoriasis in Greece:   
1.  Moderate and severe plaque psoriasis negatively 
affects  the  patients’  quality  of  life  in  every 
aspect examined compared with the population 
at large (Figure 1). 
2.  Moderate and severe plaque psoriasis represents 
an  important  cause  of  economic  burden  in 
Greece. Direct health care costs are higher than 
loss of productivity cost.  Biological medicines 
are  the  most  significant  item,  accounting  for 
77.97% of total expenses. For those that weren’t 
treated  with  biological  medicines,  the  most 
significant item was hospitalization, accounting 
for 48.61% of their total expenses. 
3.  Despite  the  treatment  used,  being  the 
conventional  methods  (topical  medicines, 
phototherapy  and  systemic  but  non  biological 
medicines) or with the introduction of biological 
medicines, clinical results were successful. 
Psoriasis causes significant psychosocial problems, 
as the results of the SF36 and DLQI questionnaires 
from  this  study  show,  which  means  that 
improvement in the quality of life, should be a major 
issue in economic considerations. Skin diseases can 
substantially diminish QoL, restricting work, social, 
and  family  relationships.  Patients  may  find  skin 
diseases more disabling than other diseases that are 
usually considered more serious, as they often feel 
that the disease alters their lives far more adversely 
than patients with cancer, diabetes or heart failure 
(Rapp SR et al, 
 1999). 
The  annual  costs  calculated  for  a  patient  with 
moderate  plaque  psoriasis  in  Greece  amounted  to 
€12,455.91 per year whereas the costs for a patient 
that were not treated with biological medicines were 
€3,856.85.  An  Italian  Cost-of-illness  study 
(Colombo GL et al
 , 2008), found that the annual 
costs per patient was €5,226.04 with a mean PASI 
score of 21.4 while a German Cost-of-Illness study 
(Sohn S. et al
  2006), showed a total annual cost per 
treated patient of €6,709.00, with a mean PASI score 
of  18.2.  Both  studies  were  performed  before  the 
induction of biological medicines in the treatment of 
the  disease.  Both  aforementioned  studies,  found 
direct  costs  higher  than  indirect  costs  and  that 
hospitalization  was  the  most  significant  item 
contributing  to  the  total  cost.  The  above  findings 
correlate  with our study  results  among  the  patient 
group that was not treated with biological medicines.  
 
Limitations 
A number of limitations of our study are well noting. 
First, we extrapolate the 3-month expenses to 1 year 
in order to be able to do comparisons with similar 
studies. Furthermore, not all the cost items, such as 
out-of-pocket expenses e.g. for transportation, were 
included in the study. Finally, we used the human 
capital  approach  in  calculating  the  loss  of 
productivity  in  the  form  of  overall  productivity 
losses  which  may  underestimates  it.  Additionally, 
the above approach may seem discriminating against 
people  with  no  market  value  such  as  the 
unemployed, retired people, and housewives. 
 
Conclusions 
 
Plaque  psoriasis  has  a  profound  impact  on  the 
affected  person’s  QoL  and  is  associated  with 
extremely  high  costs.  With  the  advent  of  the 
biological  medicines  psoriasis  costs  become  even 
higher.  However,  the  prescriptions  of  biological 
medicines are associated with a decrease in loss of 
productivity.  Strictest compliance with the disease 
management  guidelines  as  well  as  introduction  of 
generic  biologicals  medicines  will  significantly 
mitigate the increasing cost of this chronic disease. 
Finally, we deem that our study findings provides 
important  data  for  further  decision  making,  as  it International Journal of Caring Sciences      2012   May-August   Vol 5  Issue 2 
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deals  especially  with  the  economic  assessment  of 
innovative therapies for moderate and severe plaque 
psoriasis.    Further  outcome data  over  a long  time 
frame  are  needed  for  better  informed  decisions  in 
health technology assessment.   
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